Vitamin B6 and Magnesium- A Clinical Trial on ASD Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03963479 |
Recruitment Status : Unknown
Verified May 2019 by Dr. Farhana Khan, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
Recruitment status was: Recruiting
First Posted : May 24, 2019
Last Update Posted : July 31, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Autism Spectrum Disorder | Combination Product: Magnesium and Vitamin B6 | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 50 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Outcomes Assessor) |
Primary Purpose: | Supportive Care |
Official Title: | Vitamin B6 and Magnesium on Neurobehavioral Status of Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo Controlled Study |
Actual Study Start Date : | January 1, 2019 |
Estimated Primary Completion Date : | July 31, 2019 |
Estimated Study Completion Date : | July 31, 2019 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Magnesium-Vitamin B6
Magnesium (50mg) for ages 1-3 years (100mg) for ages 4-8 years (200mg) for ages 9-12 years Vitamin B6 (25mg) for ages 1-3 years (50mg) for ages 4-8 years (100mg) for ages 9-12years
|
Combination Product: Magnesium and Vitamin B6
Magnesium and Vitamin B6 will be given to the enrolled patients for 3 months |
Placebo Comparator: Placebo
Magnesium (50mg) for ages 1-3 years (100mg) for ages 4-8 years (200mg) for ages 9-12 years Vitamin B6 (25mg) for ages 1-3 years (50mg) for ages 4-8 years (100mg) for ages 9-12years
|
Combination Product: Magnesium and Vitamin B6
Magnesium and Vitamin B6 will be given to the enrolled patients for 3 months |
- Autism Spectrum Disorder [ Time Frame: 3 months ]
General observation, Cognitive Working, socialization, Communication, Sensory Dysfunction.
At first a autism will be diagnosed by DSM-5 .Then the above mention criterias along with the severity will be diagnosed by Autism Diagnostic Checklist tool by a psychologist.
- Autism Spectrum Disorder [ Time Frame: 0 month ]The Autism Diagnostic Checklist will be repeated to compare the outcomes in terms of General observation, Cognitive Working, socialization, Communication, Sensory along with the severity of the Autism.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 2 Years to 12 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Children between 2 to 12 years of age suspected ASD assessed by DSM-5 and ADCL tool
- Each patient will be free of psychoactive medication for atleast 3 months prior to the entry into the trial
- Newly diagnosed patient
- Co-morbid neurological disorder like hyperactivity
Exclusion Criteria:
- Patients with chronic diseases or any known metabolic or hormonal diseases
- Patients with any known chromosomal or genetic syndromes
- Patients unable to give informed consent
- Patients unable to travel to clinical visits or non co-operative

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03963479
Contact: Farhana Khan, MBBS | 8801674255083 | farhanakhan488@gmail.com | |
Contact: Md Sayedur Rahman, MBBS, MPhil | 8801971840757 | srkhasru@gmail.com |
Bangladesh | |
Farhana Khan | Recruiting |
Dhaka, Bangladesh, 02 | |
Contact: Md. Sayedur Rahman, MBBS, MPhil 8801971840757 srkhasru@gmail.com |
Responsible Party: | Dr. Farhana Khan, Resident, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh |
ClinicalTrials.gov Identifier: | NCT03963479 |
Other Study ID Numbers: |
BSMMU/2018/14607 |
First Posted: | May 24, 2019 Key Record Dates |
Last Update Posted: | July 31, 2019 |
Last Verified: | May 2019 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Autism Spectrum Disorder Child Development Disorders, Pervasive Neurodevelopmental Disorders Mental Disorders Vitamin B 6 Pyridoxal |
Pyridoxine Vitamins Micronutrients Physiological Effects of Drugs Vitamin B Complex |